A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Investigate the Efficacy of Telmisartan 80 mg Versus Valsartan 160 mg in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy VIVALDI-Study
Latest Information Update: 03 Nov 2021
Price :
$35 *
At a glance
- Drugs Telmisartan (Primary) ; Valsartan
- Indications Diabetic nephropathies; Hypertension; Proteinuria
- Focus Therapeutic Use
- Acronyms VIVALDI
- 01 Oct 2008 Results published in Nephrology Dialysis Transplantation.
- 14 Sep 2007 Status changed from in progress to completed
- 12 Jul 2007 The expected completion date for this trial is now 1 Dec 2005.